Peranan Mikrobiota Usus Manusia Golongan Bakteri Asam Laktat Sebagai Sumber Produksi Potensial dalam Manajemen Terapi Diabetes Melitus Tipe 1 pada Anak
DOI:
https://doi.org/10.32734/scripta.v6i1.15696Keywords:
Bakteri Asam Laktat, DMT-1, Mikrobiota Usus, Gut Microbiota (GM), Lactic Acid Bacteria, TIDMAbstract
Pendahuluan: Diabetes melitus tipe-1 (DMT-1) adalah penyakit autoimun kronis yang menyebabkan tubuh tidak dapat memproduksi insulin dalam kadar yang cukup. Menurut international diabetes federation (IDF) melaporkan secara global penderita diabetes melitus tipe-1 mencapai 8,75 juta orang dimana sebanyak 1,52 juta orang (17%) berusia di bawah 20 tahun. Angka mortalitas mencapai 18.105 kematian dari jumlah insiden 1,55 juta. Sedangkan di Indonesia jumlah kasus ini mencapai 41.817 penduduk sehingga menempati posisi teratas di ASEAN. Oleh karena itu, diperlukan sebuah inovasi manajemen terapi diabetes melitus tipe-1 terkhususnya pada anak yang memiliki keunggulan baik dalam pengobatan maupun produksi. Metode: Studi ini berupa kajian literatur yang bersumber dari beberapa pencarian internet yakni PubMed, Science Direct, ProQuest, Lancet, Google Schoolar, Garuda, Sage, dan EBSCOHost. Kajian ini disusun melalui beberapa tahap diantaranya identifikasi, skrining, dan pemenuhan kriteria inklusi dan eksklusi. Terdapat 8 artikel dari 611 artikel yang memenuhi kriteria. Pembahasan: Beberapa bakteri kelompok asam laktat sudah diuji klinis dan didapatkan hasil yang berpengaruh pada kontrol glikemik pasien diabetes melitus tipe-1. Perbaikan ditunjukkan pada kadar gula darah puasa, 2 jam postprandial, HbA1C, bahkan juga mempengaruhi C-peptida dan kadar insulin yang dibutuhkan pasien diabetes melitus tipe-1. Rute pemberian probiotik yang dilakukan juga cukup sederhana melalui oral, kecuali pada intervensi penggunaan fecal microbiota transplantation melalui injeksi. Kesimpulan: Bakteri asam laktat mempengaruhi kadar gula darah pasien, HbA1C, C-peptida, dan kadar insulin yang dibutuhkan pasien. Interval waktu pemberian probiotik juga mempengaruhi efek klinis yang diharapkan.
Introduction: Type-1 diabetes mellitus (T1DM) is a chronic autoimmune disease that causes the body to not produce enough insulin. According to the International Diabetes Federation (IDF), globally, there are 8.75 million people with type 1 diabetes mellitus, with 1.52 million (17%) of them being under 20 years old. The mortality rate reaches 18,105 deaths out of 1.55 million incidents. Meanwhile, in Indonesia, the number of cases reaches 41,817, placing it at the top position in ASEAN. Therefore, an innovative management approach for type 1 diabetes mellitus therapy, especially in children, is needed, which excels both in treatment and production. Methods: This study is a literature review sourced from several internet searches including PubMed, Science Direct, ProQuest, Lancet, Google Scholar, Garuda, Sage, and EBSCOHost. The study was conducted through several stages including identification, screening, and fulfillment of inclusion and exclusion criteria. There are 8 articles out of 611 articles that met the criteria. Discussion: Several lactic acid bacteria have been clinically tested and shown to have an effect on glycemic control in type 1 diabetes mellitus patients. Improvements are evident in fasting blood sugar levels, 2-hour postprandial levels, HbA1C, and even affect C-peptide and insulin levels required by type 1 diabetes mellitus patients. The administration route of probiotics is also quite simple, usually oral, except for interventions involving fecal microbiota transplantation via injection. Conclusion: Lactic acid bacteria affect patients' blood sugar levels, HbA1C, C-peptide, and the insulin levels required by patients. The timing interval of probiotic administration also affects the expected clinical effects.
Downloads
Published
How to Cite
Issue
Section
Copyright (c) 2024 Nindy Putri Amalia, Bima Diokta Alparisi, Riski Dimas, Dewi Anggraini
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with SCRIPTA SCORE Scientific Medical Journal agree to the following terms:
- Authors retain copyright and grant SCRIPTA SCORE Scientific Medical Journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial License that allows others to remix, adapt, build upon the work non-commercially with an acknowledgment of the work’s authorship and initial publication in SCRIPTA SCORE Scientific Medical Journal.
- Authors are permitted to copy and redistribute the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in SCRIPTA SCORE Scientific Medical Journal.